Match!
Hamzah Abu-Sbeih
University of Texas MD Anderson Cancer Center
CancerColitisDiabetes mellitusGeneral surgeryMedicine
91Publications
11H-index
444Citations
What is this?
Publications 91
Newest
#1Hamzah Abu-SbeihH-Index: 11
#2David SzafronH-Index: 1
Last. William A. RossH-Index: 28
view all 12 authors...
Source
Source
#1Shruti KhuranaH-Index: 1
#1Shruti KhuranaH-Index: 1
Last. Yinghong WangH-Index: 13
view all 5 authors...
Source
#1Hamzah Abu-SbeihH-Index: 11
#2David M. FaleckH-Index: 1
Last. Yinghong WangH-Index: 13
view all 4 authors...
Source
#1Tenglong Tang (CSU: Central South University)H-Index: 4
#2Hamzah Abu-Sbeih (University of Texas MD Anderson Cancer Center)H-Index: 11
Last. Yinghong Wang (University of Texas MD Anderson Cancer Center)H-Index: 13
view all 10 authors...
Abstract Background Data on gastrointestinal toxicities related anti-angiogenesis cancer therapy is very limited. We aim to describe the clinical, endoscopic, and histologic features and outcomes of anti-angiogenesis associated colitis and diarrhea (ACD) at a tertiary cancer center. Patients and Methods We performed a retrospective study of cancer patients who received anti-angiogenesis therapy (AAT) and underwent endoscopy for ACD symptoms during 2000-2018. Results A total of 12,045 patients re...
Source
#1Hamzah Abu-Sbeih (University of Texas MD Anderson Cancer Center)H-Index: 11
#2Faisal S. Ali (St. Joseph Hospital)H-Index: 7
Last. Yinghong Wang (University of Texas MD Anderson Cancer Center)H-Index: 13
view all 9 authors...
Background: Screening for colonic neoplasia has decreased the incidence of colorectal cancer in the United States in the past two decades. Whether personal history of noncolorectal cancer is a risk factor for colonic neoplasia has not been well studied. We assessed the risk of colorectal neoplasia in noncolorectal cancer survivors. Methods: We conducted a retrospective study of patients who had undergone colonoscopy for any indication between 2009 and 2018. Colonic adenoma detection rate and mul...
Source
#1Hamzah Abu-Sbeih (University of Texas MD Anderson Cancer Center)H-Index: 11
#2Niharika Mallepally (BCM: Baylor College of Medicine)H-Index: 2
Last. Yinghong Wang (University of Texas MD Anderson Cancer Center)H-Index: 13
view all 10 authors...
Background: Platinum-based therapy (PBT) can be limited by gastrointestinal adverse events, particularly PBT-related colitis and diarrhea (PCD). We studied clinical features, treatments, and outcomes of PCD. Methods: This was a retrospective study of cancer patients who received PBT and colonoscopic evaluation for PCD symptoms from 2009 to 2018. Results: Of 36,595 patients who received PBT, 86 (0.2%) met inclusion criteria. Median time from PBT initiation to PCD was 66 days. Regarding PBT type, ...
Source
#1Hamzah Abu-Sbeih (University of Texas MD Anderson Cancer Center)H-Index: 11
#2Faisal S. Ali (St. Joseph Hospital)H-Index: 7
Last. Yinghong WangH-Index: 13
view all 14 authors...
BACKGROUND: Patients undergoing chemotherapy are at risk for mucosal injury and neutropenia, which facilitate colonic mucosal invasion by the bowel flora and subsequent neutropenic enterocolitis, which has a poor prognosis. OBJECTIVE: This study aimed to assess the clinical features and outcomes of neutropenic enterocolitis in patients at a comprehensive cancer center. DESIGN: This is a retrospective cohort study. SETTING: The study was conducted at the University of Texas MD Anderson Cancer Cen...
Source
#1Hamzah Abu-Sbeih (University of Texas MD Anderson Cancer Center)H-Index: 11
#2David M. Faleck (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
Last. Yinghong Wang (University of Texas MD Anderson Cancer Center)H-Index: 13
view all 29 authors...
PURPOSEThe risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI advers...
9 CitationsSource
#1Ethan Miller (University of Texas MD Anderson Cancer Center)H-Index: 8
#2Hamzah Abu-Sbeih (University of Texas MD Anderson Cancer Center)H-Index: 11
Last. Naga Chalasani (IU: Indiana University)H-Index: 78
view all 7 authors...
INTRODUCTION: We conducted this study to characterize the incidence, clinical features, treatment, and outcomes of immune checkpoint inhibitor (ICI) hepatotoxicity. METHODS: Patients who received ICIs (with either single-agent or combination regimens) from January 1, 2010, to March 31, 2018, were identified. Hepatotoxicity was defined as alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN), in the absence of an alternate cause, and categorized as grade 3 (ALT 5-20x ULN) or gra...
Source
12345678910